SIMPLIFY-1:莫洛替尼对比芦可替尼的非劣效性临床试验

详细信息    查看全文 | 推荐本文 |

英文篇名：SIMPLIFY-1:A Noninferior Clinical Trial for Momelotinib Versus Ruxolitinib 作者：潘崚 ; 许娜 英文作者：PAN Ling;XU Na;Department of Hematology,West China Hospital of Sichuan University; 关键词：骨髓增殖性肿瘤 ; 莫洛替尼 ; 芦可替尼 ; 安全性 ; 有效性 英文关键词：myeloproliferative neoplasm;;Momelotinib;;Ruxolitinib;;safety;;efficacy 中文刊名：YEBM 英文刊名：The Journal of Evidence-Based Medicine 机构：四川大学华西医院血液科;南方医科大学; 出版日期：2019-04-15 出版单位：循证医学 年：2019 期：v.19 语种：中文; 页：YEBM201902006 页数：3 CN：02 ISSN：44-1548/R 分类号：15-17

摘要

<正>1文献来源Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1:A phase Ⅲ randomized trial of Momelotinib versus Ruxolitinib in Janus kinase inhibitor-n?ive patients with myelofibrosis[J]. J Clin Oncol,2017,35(34):3844-3850.
        

引文

[1]ARBER D A,ORAZI A,VARDIMAN J W,et al.The 2016revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
    [2]GUPTA V,MESA RA,DEININGER M W,et al.A phase 1/2,open-label study evaluating twice-daily administration of Momelotinib in myelofibrosis[J].Haematologica,2017,102(1):94-102.
    [3]ASSHOFF M,PETZER V,WARR M R,et al.Momelotinib inhibitsACVR1/ALK2,decreases hepcidin production,and ameliorates anemia of chronic disease in rodents[J].Blood,2017,129(13):1823-1830.